Medexus Pharmaceuticals (TSX: MDP, OTCQX: MEDXF) (@MedexusInc) header
Medexus Pharmaceuticals (TSX: MDP, OTCQX: MEDXF) (@MedexusInc) profile picture

Leading North American Specialty Pharmaceutical Company focused on hematology, rheumatology, auto-immune disease, specialty oncology and pediatrics.

Mississauga, ON & Chicago, IL
Joined February 2013
Medexus Announces Fiscal Q3 2026 Results, Driven by Continued Strong Year-To-Date Product-Level Performance of GRAFAPEX (treosulfan) for Injection medexus.com/en_US/investors/…
1
3
6
723
For more than a decade IXINITY® has been a treatment option for those living with hemophilia B. FDA-approved in April 2015, we celebrate the 10th "Approve-iversary" of #IXINITY by looking back into the archives. Please see Full Prescribing Information at IXINITY.com
2
262
Medexus Announces Normal Course Issuer Bid, or NCIB, for Its Common Shares Read the full press release: medexus.com/en_US/news-media… #MedexusInc $MDP.CA $MEDXF
1
4
842
Medexus Announces US$51.0 million in New Credit Facilities and Intention to Commence Normal Course Issuer Bid, or NCIB, for its Common Shares Read the full press release: medexus.com/en_US/investors/… #MedexusInc $MDP.CA $MEDXF
1
1
3
500
Medexus Announces Fiscal Q2 2026 Results, Driven by Strong Year-To-Date Product-Level Performance of GRAFAPEX (treosulfan) for Injection Read the full press release: medexus.com/en_US/news-media… #MedexusInc $MDP.CA $MEDXF
3
275
Medexus Schedules Second Fiscal Quarter 2026 Conference Call Read the full press release:medexus.com/en_US/investors/… #MedexusInc $MDP.CA $MEDXF
1
1
196
GRAFAPEX (treosulfan) for Injection Receives CMS Approval of New Technology Add-On Payment (NTAP) for Eligible Cases in CMS's Fiscal Year 2026 medexus.com/en_US/investors/…
1
5
206
Medexus Announces Strong Fiscal Year 2025 Results, Including Initial Results from Launch of GRAFAPEX (treosulfan) for Injection in the United States medexus.com/en_US/news-media…
1
173
The Public Prescription Drug Insurance Plan of the Régie de l'Assurance Maladie du Québec, or RAMQ, will now reimburse eligible claims made for Trecondyv®.
1
1
1
251
"This development is another important reimbursement milestone for Trecondyv® because we have now achieved public reimbursement of Trecondyv® in Canada's three most populous provinces, representing around three quarters of Canadians," said Richard Labelle, Medexus COO
2
1
279